Ignite Creation Date:
2024-05-05 @ 5:03 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00374920
Status:
COMPLETED
Last Update Posted:
2008-05-06
First Post:
2006-09-09
Brief Title:
Safety and Efficacy of MEM 1003 Versus Placebo for the Treatment of Patients With Bipolar I Disorder
Sponsor:
Memory Pharmaceuticals
Organization:
Memory Pharmaceuticals
Study Overview
Official Title:
A Multicenter Double Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of MEM 1003 for the Treatment of Patients With Bipolar I Disorder Suffering Acute Manic or Mixed Episodes
Status:
COMPLETED
Status Verified Date:
2008-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to establish the potential of MEM 1003 as a safe and effective treatment for patients with an acute manic or mixed episode of bipolar disorder
Detailed Description:
Bipolar affective disorder is one of the most common severe and persistent mental illnesses It is characterized by periods of deep prolonged and profound depressions that alternate with periods of excessively elevated andor irritable mood mania The pathophysiology of bipolar disorder is complex and can include an inheritable component administration of antidepressant medications behavioral sensitization processes and neuronal calcium dysregulation that leads to apoptosis of critical brain circuitry that regulates emotion Addressing the dysregulation in calcium levels in the central nervous system by administering compounds such as MEM 1003 may have the potential for altering the cyclical course or progression of bipolar disorder
MEM 1003 is the -enantiomer of a dihydropyridine that has been optimized for central nervous system activity It inhibits L-type Ca2 channels and within the anticipated human dosing range has more benign cardiovascular effects than other DHP L-Type calcium channel modulators
MEM 1003 is the -enantiomer of a dihydropyridine that has been optimized for central nervous system activity It inhibits L-type Ca2 channels and within the anticipated human dosing range has more benign cardiovascular effects than other DHP L-Type calcium channel modulators
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None